Elicio Therapeutics Inc. (NASDAQ:ELTX) saw its shares fall 47% on Monday after announcing that its Phase 2 AMPLIFY-7P study assessing ELI-002 7P in adjuvant pancreatic cancer did not meet the primary endpoint of disease-free survival in the intent-to-treat population.
The randomized study compared ELI-002 7P to observation in 144 patients who had undergone resection for Stage I-III mutant KRAS-driven pancreatic ductal adenocarcinoma and completed surgery plus standard locoregional therapy. While the overall trial result fell short of the prespecified primary endpoint, the company pointed to an imbalance in baseline surgical status between treatment arms that it said adversely affected outcomes.
Specifically, the arm receiving ELI-002 7P included 19% of patients with R1 resection status, compared with 10% in the observation arm. R1 resection status is described in the company statement as an established adverse prognostic factor for recurrence, and Elicio identified this difference as a negative influence on trial results.
Following the main analysis, Elicio conducted post-hoc evaluations. In the subset of patients who had achieved R0 complete resection - representing approximately 84% of the study population - treatment with ELI-002 7P produced a hazard ratio of 0.65 for disease-free survival, with a p-value of 0.048. Median disease-free survival in that R0 group was 23.8 months for the ELI-002 7P arm versus 12.8 months for observation.
Additional post-hoc landmark analyses indicated a 14% absolute disease-free survival benefit during active treatment at both the three- and six-month time points for the evaluated population during the treatment window.
The company also reported that patients who mounted the strongest mutant KRAS-specific T cell responses showed a pronounced association with improved disease-free survival. For that subset, the hazard ratio was 0.22, indicating a sizable correlation between immune response magnitude and outcome in the trial cohort.
Safety findings from the study were described as favorable: ELI-002 7P had no treatment-related discontinuations and no treatment-related deaths were reported.
In response to the results, Elicio outlined a revised Phase 3 development approach that will focus on R0 resected patients and incorporate additional dosing beyond the initial immunization and booster regimen used in AMPLIFY-7P. Financially, the company stated it expects existing cash and cash equivalents to fund operations into the fourth quarter of 2026. Management said it is evaluating multiple strategic financing and partnership opportunities to support the next stage of development.
Summary
The AMPLIFY-7P Phase 2 study did not achieve its primary endpoint for disease-free survival in the intent-to-treat group, prompting a steep decline in Elicio Therapeutics' stock. Post-hoc analyses revealed a potential benefit in the R0 resected subgroup and a strong correlation between KRAS-specific T cell responses and improved outcomes. The company plans a refined Phase 3 strategy targeting R0 patients and notes a cash runway into late 2026 while it explores financing and partnership options.
Key points
- Stock reaction: Shares fell 47% after the trial missed its primary endpoint in the intent-to-treat population - impacting investor sentiment in the biotech sector.
- Post-hoc signal: In the R0 resected subset (about 84% of participants), ELI-002 7P showed a hazard ratio of 0.65 (p=0.048) with median disease-free survival of 23.8 months versus 12.8 months for observation.
- Immune correlation and safety: Strong mutant KRAS-specific T cell responses correlated with a hazard ratio of 0.22 for disease-free survival, and the treatment had no treatment-related discontinuations or deaths.
Risks and uncertainties
- Primary endpoint failure: The trial did not meet disease-free survival in the intent-to-treat population, creating uncertainty for regulatory and commercial prospects - affecting biotech and healthcare investors.
- Baseline imbalance: An uneven distribution of R1 resections between arms may have affected results and complicates interpretation of efficacy signals for broader populations - a risk for development planning.
- Reliance on post-hoc findings: Key positive signals come from post-hoc analyses and subset evaluations, which carry inherent limitations and do not substitute for prospectively defined primary endpoint success - relevant to trial design and investor confidence.
Tags: ELTX; biotech; oncology; clinical-trials